REFERENCES
1. Hackl H, Astanina K, Wieser R. Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia. J Hematol Oncol. 2017;10:51.
2. He B, Zhao Z, Cai Q, et al. miRNA-based biomarkers, therapies, and resistance in cancer. Int J Biol Sci. 2020;16:2628-47.
3. Giovannetti E, Erozenci A, Smit J, Danesi R, Peters GJ. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol. 2012;81:103-22.
4. Bhat AA, Younes SN, Raza SS, et al. Role of non-coding RNA networks in leukemia progression, metastasis and drug resistance. Mol Cancer. 2020;19:57.
5. Seca H, Lima RT, Almeida GM, et al. Effect of miR-128 in DNA damage of HL-60 acute myeloid leukemia cells. Curr Pharm Biotechnol. 2014;15:492-502.
6. Yamamoto H, Lu J, Oba S, et al. miR-133 regulates Evi1 expression in AML cells as a potential therapeutic target. Sci Rep. 2016;6:19204.
7. Liu H, Liu M, Zhang J, Liang Y. Downregulated miR-130a enhances the sensitivity of acute myeloid leukemia cells to adriamycin. Mol Med Rep. 2020;22:2810-6.
8. Pathan M, Fonseka P, Chitti SV, et al. Vesiclepedia 2019: a compendium of RNA, proteins, lipids and metabolites in extracellular vesicles. Nucleic Acids Res. 2019;47:D516-9.
9. Fontana F, Carollo E, Melling GE, Carter DRF. Extracellular vesicles: emerging modulators of cancer drug resistance. Cancers. 2021;13:749.
10. Cariello M, Squilla A, Piacente M, Venutolo G, Fasano A. Drug resistance: the role of exosomal miRNA in the microenvironment of hematopoietic tumors. Molecules. 2022;28:116.
11. Guo QR, Wang H, Yan YD, et al. The role of exosomal microRNA in cancer drug resistance. Front Oncol. 2020;10:472.
12. Wu J, Zhang Y, Li X, et al. Exosomes from bone marrow mesenchymal stem cells decrease chemosensitivity of acute myeloid leukemia cells via delivering miR-10a. Biochem Biophys Res Commun. 2022;622:149-56.
13. Li H, Xie C, Lu Y, Chang K, Guan F, Li X. Exosomal miR92a promotes cytarabine resistance in myelodysplastic syndromes by activating Wnt/β-catenin signal pathway. Biomolecules. 2022;12:1448.
14. Jiang Y, Xiao S, Huang S, et al. Extracellular vesicle-mediated regulation of imatinib resistance in chronic myeloid leukemia via the miR-629-5p/SENP2/PI3K/AKT/mTOR axis. Hematology. 2024;29:2379597.
15. Min QH, Wang XZ, Zhang J, et al. Exosomes derived from imatinib-resistant chronic myeloid leukemia cells mediate a horizontal transfer of drug-resistant trait by delivering miR-365. Exp Cell Res. 2018;362:386-93.
16. Bouvy C, Wannez A, Laloy J, Chatelain C, Dogné JM. Transfer of multidrug resistance among acute myeloid leukemia cells via extracellular vesicles and their microRNA cargo. Leuk Res. 2017;62:70-6.
17. Fishman A, T Lamm A. QsRNA-seq: a protocol for generating libraries for high-throughput sequencing of small RNAs. Bio Protoc. 2019;9:e3179.
18. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139-40.
19. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: targets and expression. Nucleic Acids Res. 2008;36:D149-53.
20. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R. Fast and effective prediction of microRNA/target duplexes. RNA. 2004;10:1507-17.
21. Deng YY, Li JQ, Wu SF, et al. Integrated nr database in protein annotation system and its localization. Comput Eng. 2006;32:71-2.
22. Apweiler R, Bairoch A, Wu CH, et al. UniProt: the Universal Protein knowledgebase. Nucleic Acids Res. 2004;32:D115-9.
23. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25:25-9.
24. Tatusov RL, Galperin MY, Natale DA, Koonin EV. The COG database: a tool for genome-scale analysis of protein functions and evolution. Nucleic Acids Res. 2000;28:33-6.
25. Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M. The KEGG resource for deciphering the genome. Nucleic Acids Res. 2004;32:D277-80.
26. Koonin EV, Fedorova ND, Jackson JD, et al. A comprehensive evolutionary classification of proteins encoded in complete eukaryotic genomes. Genome Biol. 2004;5:R7.
28. Mao X, Cai T, Olyarchuk JG, Wei L. Automated genome annotation and pathway identification using the KEGG Orthology (KO) as a controlled vocabulary. Bioinformatics. 2005;21:3787-93.
29. Trotman LC, Wang X, Alimonti A, et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell. 2007;128:141-56.
30. Pei X, Mladenov E, Soni A, Li F, Stuschke M, Iliakis G. PTEN loss enhances error-prone DSB processing and tumor cell radiosensitivity by suppressing RAD51 expression and homologous recombination. Int J Mol Sci. 2022;23:12876.
31. Naci D, Berrazouane S, Barabé F, Aoudjit F. Cell adhesion to collagen promotes leukemia resistance to doxorubicin by reducing DNA damage through the inhibition of Rac1 activation. Sci Rep. 2019;9:19455.
32. Fadeev RS, Solovieva ME, Slyadovskiy DA, et al. Cell aggregation increases drug resistance of acute myeloid leukemia cells. Biochem Moscow Suppl Ser A. 2015;9:135-43.
33. Wu T, Chen Y, Du Y, Tao J, Zhou Z, Yang Z. Serum exosomal miR-92b-5p as a potential biomarker for acute heart failure caused by dilated cardiomyopathy. Cell Physiol Biochem. 2018;46:1939-50.
34. Yang Q, Zhao S, Shi Z, et al. Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2/STAT3 signaling. J Exp Clin Cancer Res. 2021;40:120.
35. Zhu Z, Luo L, Xiang Q, et al. MiRNA-671-5p promotes prostate cancer development and metastasis by targeting NFIA/CRYAB axis. Cell Death Dis. 2020;11:949.
36. Jin W, Shi J, Liu M. Overexpression of miR-671-5p indicates a poor prognosis in colon cancer and accelerates proliferation, migration, and invasion of colon cancer cells. Onco Targets Ther. 2019;12:6865-73.
37. Lin JC, Kuo CY, Tsai JT, Liu WH. miR-671-5p Inhibition by MSI1 promotes glioblastoma tumorigenesis via radioresistance, tumor motility and cancer stem-like cell properties. Biomedicines. 2021;10:21.
38. Gungormez C, Gumushan Aktas H, Dilsiz N, Borazan E. Novel miRNAs as potential biomarkers in stage II colon cancer: microarray analysis. Mol Biol Rep. 2019;46:4175-83.
39. Sun L, Zhou H, Zhao X, Zhang H, Wang Y, Li G. Small RNA sequencing identified miR-3180 as a potential prognostic biomarker for Chinese hepatocellular carcinoma patients. Front Genet. 2023;14:1102171.
40. Yang L, Zhang X, Liu C, Zhang J, Dong B. MiR-92 family members form a cluster required for notochord tubulogenesis in urochordate ciona savignyi. Genes. 2021;12:406.
41. Høgdall D, O'Rourke CJ, Larsen FO, et al. Whole blood microRNAs capture systemic reprogramming and have diagnostic potential in patients with biliary tract cancer. J Hepatol. 2022;77:1047-58.
42. Barquet-Muñoz SA, Pedroza-Torres A, Perez-Plasencia C, et al. microRNA profile associated with positive lymph node metastasis in early-stage cervical cancer. Curr Oncol. 2022;29:243-54.
43. Xu J, Wen J, Li S, et al. Immune-related nine-microRNA signature for predicting the prognosis of gastric cancer. Front Genet. 2021;12:690598.
44. Kan JY, Shih SL, Yang SF, et al. Exosomal microRNA-92b is a diagnostic biomarker in breast cancer and targets survival-related MTSS1L to promote tumorigenesis. Int J Mol Sci. 2024;25:1295.
45. Kim DH, Park H, Choi YJ, et al. Identification of exosomal microRNA panel as diagnostic and prognostic biomarker for small cell lung cancer. Biomark Res. 2023;11:80.
46. Murillas R, Simms KS, Hatakeyama S, Weissman AM, Kuehn MR. Identification of developmentally expressed proteins that functionally interact with Nedd4 ubiquitin ligase. J Biol Chem. 2002;277:2897-907.
47. Sharma P, Murillas R, Zhang H, Kuehn MR. N4BP1 is a newly identified nucleolar protein that undergoes SUMO-regulated polyubiquitylation and proteasomal turnover at promyelocytic leukemia nuclear bodies. J Cell Sci. 2010;123:1227-34.
48. Chiyomaru T, Yamamura S, Zaman MS, et al. Genistein suppresses prostate cancer growth through inhibition of oncogenic microRNA-151. PLoS One. 2012;7:e43812.
49. Xu J, Jiang N, Shi H, Zhao S, Yao S, Shen H. miR-28-5p promotes the development and progression of ovarian cancer through inhibition of N4BP1. Int J Oncol. 2017;50:1383-91.
50. Hu H, Jiang L, Kang X, Zhang L, Zeng S. Extracellular vesicles derived from lung cancer cells promote the progression of lung cancer by delivering miR-151a-5p. Exp Cell Res. 2023;425:113526.
51. Oberst A, Malatesta M, Aqeilan RI, et al. The Nedd4-binding partner 1 (N4BP1) protein is an inhibitor of the E3 ligase Itch. Proc Natl Acad Sci U S A. 2007;104:11280-5.
52. Wang X, Shi Y, Wang J, Huang G, Jiang X. Crucial role of the C-terminus of PTEN in antagonizing NEDD4-1-mediated PTEN ubiquitination and degradation. Biochem J. 2008;414:221-9.
53. Wang ZW, Hu X, Ye M, Lin M, Chu M, Shen X. NEDD4 E3 ligase: functions and mechanism in human cancer. Semin Cancer Biol. 2020;67:92-101.
54. Fouladkou F, Landry T, Kawabe H, et al. The ubiquitin ligase Nedd4-1 is dispensable for the regulation of PTEN stability and localization. Proc Natl Acad Sci U S A. 2008;105:8585-90.
55. Wang X, Trotman LC, Koppie T, et al. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell. 2007;128:129-39.
56. Drinjakovic J, Jung H, Campbell DS, Strochlic L, Dwivedy A, Holt CE. E3 ligase Nedd4 promotes axon branching by downregulating PTEN. Neuron. 2010;65:341-57.
57. Dong L, Li Y, Liu L, et al. Smurf1 suppression enhances temozolomide chemosensitivity in glioblastoma by facilitating PTEN nuclear translocation. Cells. 2022;11:3302.
58. Bonilla B, Hengel SR, Grundy MK, Bernstein KA. RAD51 gene family structure and function. Annu Rev Genet. 2020;54:25-46.
59. Xie C, Drenberg C, Edwards H, et al. Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51. PLoS One. 2013;8:e79106.
60. Lai TH, Ewald B, Zecevic A, et al. HDAC inhibition induces microRNA-182, which targets RAD51 and impairs HR repair to sensitize cells to sapacitabine in acute myelogenous leukemia. Clin Cancer Res. 2016;22:3537-49.
61. Huang ZJ, Zhu JJ, Yang XY, Biskup E. NEDD4 promotes cell growth and migration via PTEN/PI3K/AKT signaling in hepatocellular carcinoma. Oncol Lett. 2017;14:2649-56.
62. Wen W, Li J, Wang L, et al. Inhibition of NEDD4 inhibits cell growth and invasion and induces cell apoptosis in bladder cancer cells. Cell Cycle. 2017;16:1509-14.
